Physician profile
Mark Thomas St Lawrence
NPI 1962446377
$11,544.10
in general payments reported to CMS, 2019-2025
52 companies · $2,219 in 2025
The $2,219 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,400 · 2022: $1,986 · 2023: $1,911 · 2024: $2,028 · 2025: $2,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,157.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,364.29 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,079.69 | 2021 | |
| Lilly USA, LLC | $1,010.99 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $874.85 | 2021-2025 | |
| Glaxosmithkline, LLC. | $707.78 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $609.28 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $570.96 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $546.82 | 2021-2025 | |
| Amgen INC. | $471.29 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.29 | 2021-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $328.87 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $294.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $284.89 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $267.72 | 2021-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.32 | 2021-2025 | Xifaxan |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $250.95 | 2021-2025 | Capvaxive, Verquvo, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $234.22 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $187.12 | 2021-2025 | |
| Antares Pharma, INC. | $175.21 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Radius Health, INC. | $154.97 | 2022-2025 | |
| Dexcom, INC. | $119.87 | 2021-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $110.06 | 2021-2023 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $86.45 | 2023-2024 | Inspire |
| Daiichi Sankyo INC. | $82.56 | 2021-2025 | Injectafer |
| Insmed, INC. | $80.89 | 2025 | Arikayce |
| Medtronic, INC. | $72.23 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Alk-Abello, INC | $70.82 | 2024-2025 | Odactra, Ragwitek, Grastek |
| Novartis Pharmaceuticals Corporation | $70.74 | 2022 | |
| Amarin Pharma, INC. | $61.62 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.82 | 2022 | |
| Eisai INC. | $55.59 | 2021 | |
| Tolmar, INC. | $55.40 | 2024-2025 | Jatenzo |
| Jazz Pharmaceuticals INC. | $53.09 | 2021 | |
| Sumitomo Pharma America, INC. | $52.67 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $51.57 | 2023-2025 | Veozah |
| Tris Pharma INC | $49.27 | 2023-2025 | Dyanavel Xr |
| Lundbeck LLC | $44.38 | 2024-2025 | Rexulti |
| Viiv Healthcare Company | $36.60 | 2024 | Apretude |
| Sanofi Pasteur INC. | $33.20 | 2023 | |
| Mannkind Corporation | $32.71 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.68 | 2023 | Quviviq |
| Corium, LLC | $27.44 | 2024 | Azstarys |
| Axsome Therapeutics, INC. | $22.24 | 2025 | Auvelity |
| Ucb, INC. | $22.07 | 2022 | |
| Amneal Pharmaceuticals LLC | $21.27 | 2025 | Unithroid |
| Halozyme INC | $19.52 | 2023 | |
| Ibsa Pharma INC. | $18.58 | 2021 | |
| Almatica Pharma LLC | $18.50 | 2024 | Loreev Xr |
| Horizon Therapeutics Plc | $17.76 | 2022 | |
| Currax Pharmaceuticals LLC | $14.98 | 2025 | Contrave |
| Kowa Pharmaceuticals America, INC. | $14.28 | 2021 | |
| Alkermes, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark St Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.